Paragon Associates & Paragon Associates II Joint Venture Takes Position in Quanterix Corporation $QTRX

Paragon Associates & Paragon Associates II Joint Venture acquired a new position in shares of Quanterix Corporation (NASDAQ:QTRX) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 100,671 shares of the company’s stock, valued at approximately $547,000. Quanterix accounts for about 1.0% of Paragon Associates & Paragon Associates II Joint Venture’s investment portfolio, making the stock its 12th largest holding.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ameriprise Financial Inc. increased its holdings in Quanterix by 14.0% in the second quarter. Ameriprise Financial Inc. now owns 4,236,877 shares of the company’s stock valued at $28,175,000 after buying an additional 521,639 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Quanterix by 4.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,647,515 shares of the company’s stock worth $14,376,000 after buying an additional 118,565 shares during the last quarter. William Blair Investment Management LLC lifted its holdings in Quanterix by 16.6% during the 3rd quarter. William Blair Investment Management LLC now owns 1,315,280 shares of the company’s stock worth $7,142,000 after buying an additional 187,299 shares during the last quarter. Blue Water Life Science Advisors LP boosted its position in shares of Quanterix by 157.3% during the 2nd quarter. Blue Water Life Science Advisors LP now owns 957,747 shares of the company’s stock worth $6,369,000 after acquiring an additional 585,572 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Quanterix by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 887,080 shares of the company’s stock worth $5,900,000 after acquiring an additional 21,210 shares in the last quarter. Institutional investors and hedge funds own 86.48% of the company’s stock.

Quanterix Price Performance

NASDAQ QTRX opened at $5.06 on Friday. The company has a fifty day moving average of $6.42 and a two-hundred day moving average of $6.01. The company has a market capitalization of $237.52 million, a PE ratio of -2.01 and a beta of 1.05. Quanterix Corporation has a 1 year low of $4.05 and a 1 year high of $8.77.

Quanterix (NASDAQ:QTRX) last posted its earnings results on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.11). Quanterix had a negative return on equity of 23.96% and a negative net margin of 77.14%.The firm had revenue of $41.40 million for the quarter, compared to analyst estimates of $37.95 million. On average, research analysts expect that Quanterix Corporation will post -0.98 earnings per share for the current year.

Wall Street Analyst Weigh In

QTRX has been the topic of several research analyst reports. Wall Street Zen raised Quanterix from a “sell” rating to a “hold” rating in a research report on Monday, December 29th. Canaccord Genuity Group upped their price target on Quanterix from $5.00 to $8.00 and gave the company a “hold” rating in a report on Monday, December 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Quanterix in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $11.33.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.